ArticleItalian journal of pediatrics2021
Detection of endocrine disorders in young children with multi-transfused thalassemia major.
Article in Italian journal of pediatrics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- The impact of chelation compliance in health outcome and health related quality of life in thalassaemia patients: a systematic review.Health and quality of life outcomes · 2024Pooled it
- Endocrinopathies and growth in a UK cohort of children with transfusion dependent thalassaemia.British journal of haematology · 2026Observational
- Epidemiological Patterns and Determinants of Subclinical and Overt Hypothyroidism in a Clinical Cohort from the Hail Region, Saudi Arabia: A Retrospective Cross-Sectional and Cluster Analysis Study.Clinics and practice · 2026Article
- Regulation of mitochondrial iron homeostasis in tumor cells.Molecular medicine (Cambridge, Mass.) · 2026Review
- Endocrine dysfunctions in patients with beta thalassemia major: a single-center retrospective study from Basrah.F1000Research · 2026Article
- Evaluation of Children and Adolescents with Thalassemia Major in Terms of Osteoporosis: A Single-Centre Experience.Journal of clinical medicine · 2025Article
- Endocrine complications in patients with β-thalassemia major receiving iron-chelation therapy.Therapeutic advances in endocrinology and metabolism · 2025Article
- Reproductive Health in Women with Major β-Thalassemia: Evaluating Ovarian Reserve and Endocrine Complications.Metabolites · 2024Review
- Assessment of Serum Vitamin D and Parathyroid Hormone in Children With Beta Thalassemia Major: A Case-Control Study.Cureus · 2024Article
- Predicting Thalassemia Using Feature Selection Techniques: A Comparative Analysis.Diagnostics (Basel, Switzerland) · 2023Article
- Nutritional studies in patients with β-thalassemia major: A short review.Acta bio-medica : Atenei Parmensis · 2023Review
- Iron overload induces islet β cell ferroptosis by activating ASK1/P-P38/CHOP signaling pathway.PeerJ · 2023Article
- New insights in pediatrics in 2021: choices in allergy and immunology, critical care, endocrinology, gastroenterology, genetics, haematology, infectious diseases, neonatology, neurology, nutrition, palliative care, respiratory tract illnesses and telemedicine.Italian journal of pediatrics · 2022Review
- New Entity-Thalassemic Endocrine Disease: Major Beta-Thalassemia and Endocrine Involvement.Diagnostics (Basel, Switzerland) · 2022Review
- [Endocrine disorders in patients with transfusion-dependent hereditary anemias].Problemy endokrinologii · 2022Article
- Link between Genotype and Multi-Organ Iron and Complications in Children with Transfusion-Dependent Thalassemia.Journal of personalized medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBeta thalassemia major (TM) is the most common inherited genetic disorder worldwide. Patients are at risk of iron overload, which leads to various forms of tissue damage, including endocrinopathies. The aim of this study was to evaluate the prevalence and risk factors of endocrine disorders in young patients with multi-transfused TM receiving iron chelation therapy.
methodsThe inclusion criteria included all known cases of TM according to hemoglobin electrophoresis data, aged 12 years or younger, during the study period. The patient's age, gender, parent's consanguinity, clinical examination, and types of iron chelating agents used were recorded. Serum ferritin level, complete blood count (CBC), blood glucose homeostasis, thyroid, and parathyroid functions were determined.
resultsOne hundred twenty patients met the inclusion criteria; 70% of them had malnutrition. The presence of endocrine disorders was observed in 28/120 (23.33%) patients. The most common endocrine disorders were thyroid disorders, either subclinical or clinical hypothyroidism in 11/120 (9.17%) patients, followed by abnormalities in glucose homeostasis 9/120 (7.5%). The prevalence of impaired glucose tolerance, impaired fasting glucose, and diabetes mellitus in the present study was 5 (4.17%), 4 (3.33%), and 0 (00%), respectively, while the least frequent endocrine disorder seen in our patients was hypoparathyroidism in 8/120 (6.66%). We noted that high serum ferritin levels and poor patient compliance to therapy were significantly associated with increased endocrine disorders (OR 0.98, 95% CI 0.96-0.99, P = 0.003 and OR 0.38, 95% CI 0.16:0.93, P = 0.03, respectively). Combined chelating iron agents significantly decreased the prevalence of endocrine disorders when compared with monotherapy (OR 0.40, 95% CI 0.16:0.97, P = 0.04).
conclusionEndocrine disorders could occur in TM patients early before or equal to 12 years of life in about one-fourth of the patients. A high serum ferritin level and poor patient compliance to therapy were significantly associated with increased endocrine disorders. Combined iron-chelating agents were associated with a decreased prevalence of endocrine disorders when compared with monotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.